S. H. Shao

Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma.

K. Flaherty, D. Ryan, T. Bekaii-Saab, 2020, European journal of cancer.

Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients

J. O’Shaughnessy, S. Vukelja, J. W. Smith, 2013, Breast Cancer Research and Treatment.

Case report: splenic sequestration and multiorgan failure as the presenting manifestation of hemoglobin SC disease.

E. Orringer, S. H. Shao, 1996, The American journal of the medical sciences.

Sickle cell intrahepatic cholestasis: approach to a difficult problem.

E. Orringer, S. H. Shao, S. Shao, 1995, The American journal of gastroenterology.

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

J. Burke, J. Reeves, B. Cheson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.

K. Flaherty, D. Ryan, T. Bekaii-Saab, 2017 .

Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

J. Burke, J. Reeves, B. Cheson, 2020 .